AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Subfamily B2 == Subfamily B2 (also known as the adhesion G protein-coupled receptor family) contains receptors with long extracellular N-termini, such as the leukocyte cell-surface antigen CD97; calcium-independent receptors for latrotoxin and brain-specific angiogenesis inhibitor receptors amongst others. However, in some more recent classifications, they are no longer considered part of the same family as secretin (due to significant differences, like autocatalytic processing and different cell functions).
=== Andy: Get The Poison Out === First aired: 4 November 2010 Meet Andy, the self-appointed king of Fresno. He is an obnoxious bully who makes life miserable for his victims, Steven and Taylor. He also makes the biggest mistake of calling out Mayhem, so Mayhem brings out "the greatest fighter he has ever known" to take care of Andy. That fighter turns out to be Mayhem himself. After easily being tapped out 5 times in the first round and knocked out in the second round, Steven and Taylor won $10,000. After the fight, Mayhem tells a humbled Andy that he had to deal with bullies most of his life and implores him to change his ways because he eventually will come across someone that is bigger, badder and meaner than Andy himself.
Source: When tendons are injured, tendon cells are activated to promote repair, but this process can be slow. Recent research has focused on improving tendon healing through therapies such as stem cell injections, growth factors, and tissue-engineered approaches to enhance tendon cell activity and regeneration.
== Phylogeny == The Ecdysozoa include the following phyla: Arthropoda, Onychophora, Tardigrada, Kinorhyncha, Priapulida, Loricifera, Nematoda, and Nematomorpha. A few extinct taxa have been classified as stem group ecdysozoans, such as Uncus dzaugisi and Acosmia. Other groups such as the gastrotrichs, have been considered possible members but lack the main characters of the group, and are now placed elsewhere. The Arthropoda, Onychophora, and Tardigrada have been grouped together as the Panarthropoda because they are distinguished by segmented body plans. Dunn et al. in 2008 suggested that the tardigrada could be grouped along with the nematodes, leaving Onychophora as the sister group to the arthropods. The non-panarthropod members of Ecdysozoa have been grouped as Cycloneuralia but they are more usually considered paraphyletic in representing the primitive condition from which the Panarthropoda evolved. A modern consensus phylogenetic tree for Ecdysozoa is shown below, mainly based on the one supported by Giribet & Edgecombe (2017), which summarizes relationships found in recent ecdysozoan phylogenies:
== Sources == Cox H (2000). The Global Cigarette: Origins and Evolution of British American Tobacco, 1880-1945. Oxford University Press. ISBN 978-0-19-829221-0. "E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General" (PDF). United States Department of Health and Human Services. Surgeon General of the United States. 2016. pp. 1–298. Archived (PDF) from the original on October 9, 2022. This article incorporates text from this source, which is in the public domain. "Electronic nicotine delivery systems" (PDF). World Health Organization. July 21, 2014. pp. 1–13. Wilder N, Daley C, Sugarman J, Partridge J (April 2016). "Nicotine without smoke: Tobacco harm reduction". Royal College of Physicians. UK. pp. 1–191. Archived from the original on May 5, 2016. Retrieved June 2, 2019.
Sources: en.wikipedia.org
Binding to the solid phase may be achieved by column chromatography whereby the solid medium is packed onto a column, the initial mixture run through the column to allow settling, a wash buffer run through the column and the elution buffer subsequently applied to the column and collected. These steps are usually done at ambient pressure. Alternatively, binding may be achieved using a batch treatment, for example, by adding the initial mixture to the solid phase in a vessel, mixing, separating the solid phase, removing the liquid phase, washing, re-centrifuging, adding the elution buffer, re-centrifuging and removing the elute. Sometimes a hybrid method is employed such that the binding is done by the batch method, but the solid phase with the target molecule bound is packed onto a column and washing and elution are done on the column. The ligands used in affinity chromatography are obtained from both organic and inorganic sources. Examples of biological sources are serum proteins, lectins and antibodies. Inorganic sources are moronic acid, metal chelates and triazine dyes. A third method, expanded bed absorption, which combines the advantages of the two methods mentioned above, has also been developed. The solid phase particles are placed in a column where liquid phase is pumped in from the bottom and exits at the top. The gravity of the particles ensure that the solid phase does not exit the column with the liquid phase.
=== Awards === 2023 Pulitzer Prize for Fiction, won Note: Hernan Diaz's Trust also won the award. This is the first time two books shared the award in its history. 2023 Orwell Prize for Political Fiction, shortlist 2023 Women's Prize for Fiction, won Note: The first author to win the prize twice; previously won in 2010 for The Lacuna. 2022 James Tait Black Prize for Fiction, won
== Professional life == Following university, Eltenton began work in 1930 at the British Cotton Research Institute. In the summer of 1931 however, Eltenton visited a friend he had known at Cambridge, Yulii Khariton, at the Institute of Problems of Chemical Physics in Leningrad. He was offered a post in there, and moved to the USSR to work from 1933 until 1938, only leaving because, with the Soviet Great Purge, there was suspicion of foreigners. Like many others, his visa was not renewed, so he returned to England. The same year he published a paper in the prestigious journal Nature, showing the first identification of free radicals by mass spectrometer, and was invited to the research laboratories of Shell Development Corporation, California to build one of the first mass spectrometers in the US. Here he produced significant work on free radical mass spectrometry. In 1947 he returned to England, joining the research laboratory of Shell plc at Ellesmere Port, later transferring to the physics laboratory of Stanlow Refinery and producing a number of patents.
=== Humans === Cocaine and other local anesthetics are known to produce cardiotoxicity by blocking sodium channels. However, no reports have been published of these same effects of cardiotoxicity associated with dimethocaine. There has been little research about toxicity of dimethocaine in humans, and therefore the exact lethal or pharmacological doses are unknown.
Helium–cadmium lasers are a common source of blue or ultraviolet laser light. Lasers at wavelengths of 325, 354 and 442 nm are made using this gain medium; some models can switch between these wavelengths. They are notably used in fluorescence microscopy as well as various laboratory uses requiring laser light at these wavelengths.
Sources: en.wikipedia.org
=== U.S. relations with Marshall Islands === Section 177 of the 1983 Compact of Free Association between the governments of the United States and the Marshall Islands establishes a process for Marshallese to make a claim against the United States government as a result of damage and injury caused by nuclear testing. That same year, an agreement was signed to implement Section 177, which established a US$150 million trust fund. The fund was intended to generate US$18 million a year, which would be payable to claimants on an agreed-upon schedule. If the US$18 million a year generated by the fund was not enough to cover claims, the principal of the fund could be used. A Marshall Islands Nuclear Claims Tribunal was established to adjudicate claims. In 2000, the tribunal made a compensation award to the people of Enewetak consisting of US$107.8 million for environmental restoration; US$244 million in damages to cover economic losses caused by loss of access and use of the atoll; and US$34 million for hardship and suffering. In addition, as of the end of 2008, another US$96.658 million in individual damage awards were made. Only US$73.526 million of the individual claims award has been paid, however, and no new awards were made between the end of 2008 and May 2010. Due to stock market losses, payments rates that have outstripped fund income, and other issues, the fund was nearly exhausted, as of May 2010, and unable to make any additional awards or payments.
=== Clinical trials === As of 2023, an ERAP1 Inhibitor (GRWD5769) developed by Grey Wolf Therapeutics has entered phase I/II. Its safety, tolerability, efficacy, and pharmacokinetics are being evaluated in patients with viral associated solid tumours (head and neck squamous cell carcinoma, cervical cancer, and hepatocellular carcinoma) that are particularly sensitive to ERAP1 inhibition, as monotherapy, or in combination with PD-1 immune checkpoint Inhibitor Libtayo® (cemiplimab).
Wood has been a key material in construction since ancient times, so its preservation by coating has received much attention. Efforts to improve the performance of wood coatings continue. Coatings are used to alter tribological properties and wear characteristics. These include anti-friction, wear and scuffing resistance coatings for rolling-element bearings Architectural coatings or paints are used to paint the exteriors and interiors of buildings, often called or external masonry coatings. Clear varnishes and lacquers are generally excluded. Such products are usually designated for specific purposes such as roof coatings, wall paints, or deck finishes. Coatings are eco-friendly building material that increases the efficiency of energy used and reduces impact on human well-being and the environment. The coatings are typically applied with brushes, rollers or sprayers. Wall coatings come in a variety of types, some of which can be applied by amateurs and DIYers without specialized training or equipment. For example, simple paint or primers can often be applied using brushes or rollers, and many people successfully complete such projects themselves. Most masonry surfaces can be treated an exterior wall coating, such as render, pebbledash, stone, stucco or brick.
== Occurrence and reactions == Like most amino acids, pipecolic acid is a chelating agent. One complex is Cu(HNC5H9CO2)2(H2O)2. Pipecolic acid was identified in the Murchison meteorite. It also occurs in the leaves of the genus Myroxylon, a tree from South America.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.